Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

ABSTRACT: Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC). Over the last decade, these findings have led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Already, the standard of care for patients with advanced-stage NSCLC is shifting from selecting therapy empirically based on a patient's clinicopathologic features to using biomarker-driven treatment algorithms based on the molecular profile of a patient's tumor. This approach is currently best exemplified by treating patients with NSCLC with first-line tyrosine kinase inhibitors when their cancers harbor gain-of-function hotspot mutations in the epidermal gr

SUBMITTER: Li T 

PROVIDER: S-EPMC3589700 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature